[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1904494T3 - Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer - Google Patents

Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer

Info

Publication number
DK1904494T3
DK1904494T3 DK06735794.7T DK06735794T DK1904494T3 DK 1904494 T3 DK1904494 T3 DK 1904494T3 DK 06735794 T DK06735794 T DK 06735794T DK 1904494 T3 DK1904494 T3 DK 1904494T3
Authority
DK
Denmark
Prior art keywords
imidazo
vegf
inhibitors
pyridine compounds
pyridine
Prior art date
Application number
DK06735794.7T
Other languages
English (en)
Inventor
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Yvonne Yee Mai Yip
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1904494T3 publication Critical patent/DK1904494T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06735794.7T 2005-02-24 2006-02-23 Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer DK1904494T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (1)

Publication Number Publication Date
DK1904494T3 true DK1904494T3 (da) 2011-02-21

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06735794.7T DK1904494T3 (da) 2005-02-24 2006-02-23 Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer

Country Status (34)

Country Link
US (1) US7666879B2 (da)
EP (1) EP1904494B1 (da)
JP (1) JP5055136B2 (da)
KR (1) KR100904938B1 (da)
CN (1) CN101128461B (da)
AR (1) AR056186A1 (da)
AT (1) ATE490254T1 (da)
AU (1) AU2006216710B2 (da)
BR (1) BRPI0609047A2 (da)
CA (1) CA2599124C (da)
CR (1) CR9331A (da)
CY (1) CY1111154T1 (da)
DE (1) DE602006018615D1 (da)
DK (1) DK1904494T3 (da)
DO (1) DOP2006000051A (da)
EA (1) EA011691B1 (da)
ES (1) ES2354716T3 (da)
HK (1) HK1118284A1 (da)
HR (1) HRP20100677T1 (da)
IL (1) IL184717A (da)
MA (1) MA29433B1 (da)
MX (1) MX2007010326A (da)
NO (1) NO20074666L (da)
NZ (2) NZ584753A (da)
PE (1) PE20061098A1 (da)
PL (1) PL1904494T3 (da)
PT (1) PT1904494E (da)
RS (1) RS51590B (da)
SI (1) SI1904494T1 (da)
TN (1) TNSN07323A1 (da)
TW (1) TW200640924A (da)
UA (1) UA91535C2 (da)
WO (1) WO2006091671A1 (da)
ZA (1) ZA200707136B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
AU2007337886C1 (en) 2006-12-22 2014-10-16 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
EP2212323B1 (en) 2007-10-17 2012-08-15 Novartis AG Imidazo [1,2-a] pyridine derivatives useful as alk inhibitors
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
DK2900238T3 (da) * 2012-09-28 2018-03-12 Univ Vanderbilt Kondenserede heterocykliske forbindelser som selektive bmp-inhibitorer
BR112015008200A2 (pt) * 2012-11-29 2017-07-04 Hoffmann La Roche derivados de imidazopiridina
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
KR102430072B1 (ko) 2013-12-16 2022-08-10 에이비에스 디벨롭먼트 원 인코포레이티드 P2x3 및/또는 p2x2/3 화합물 및 방법
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
EP3152194B8 (en) * 2014-06-03 2019-10-09 Arizona Board of Regents on Behalf of the University of Arizona Benzimidazole derivatives
HUE046008T2 (hu) 2014-07-17 2020-02-28 Sunshine Lake Pharma Co Ltd I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017040993A1 (en) * 2015-09-03 2017-03-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1a and uses thereof
EP3430005B1 (en) * 2016-03-16 2021-12-08 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
WO2020160074A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
CN111574521A (zh) * 2019-02-18 2020-08-25 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
EP3990457A4 (en) * 2019-06-25 2023-09-13 Sinopsee Therapeutics COMPOUNDS FOR THE TREATMENT OF EYE DISEASES
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
DE60024830T2 (de) 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
CA2453147A1 (en) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
ATE381332T1 (de) * 2002-05-02 2008-01-15 Merck & Co Inc Tyrosinkinase-hemmer
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7262199B2 (en) * 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
US7504412B2 (en) 2003-08-15 2009-03-17 Banyu Pharmaceuticals, Co., Ltd. Imidazopyridine derivatives

Also Published As

Publication number Publication date
IL184717A0 (en) 2007-12-03
EA200701802A1 (ru) 2008-02-28
CA2599124C (en) 2013-08-06
JP5055136B2 (ja) 2012-10-24
NZ560402A (en) 2010-06-25
EP1904494B1 (en) 2010-12-01
PE20061098A1 (es) 2006-10-20
NO20074666L (no) 2007-11-09
AU2006216710A1 (en) 2006-08-31
MX2007010326A (es) 2007-10-16
DE602006018615D1 (de) 2011-01-13
EP1904494A1 (en) 2008-04-02
ES2354716T3 (es) 2011-03-17
TNSN07323A1 (en) 2008-12-31
PT1904494E (pt) 2010-12-23
CA2599124A1 (en) 2006-08-31
SI1904494T1 (sl) 2011-02-28
RS51590B (en) 2011-08-31
WO2006091671A1 (en) 2006-08-31
ATE490254T1 (de) 2010-12-15
US20090227622A1 (en) 2009-09-10
ZA200707136B (en) 2008-11-26
PL1904494T3 (pl) 2011-04-29
KR100904938B1 (ko) 2009-06-29
HK1118284A1 (en) 2009-02-06
TW200640924A (en) 2006-12-01
DOP2006000051A (es) 2006-08-31
JP2008531574A (ja) 2008-08-14
CR9331A (es) 2008-03-31
EA011691B1 (ru) 2009-04-28
UA91535C2 (en) 2010-08-10
NZ584753A (en) 2011-06-30
MA29433B1 (fr) 2008-05-02
IL184717A (en) 2011-11-30
CY1111154T1 (el) 2015-06-11
KR20070099029A (ko) 2007-10-08
US7666879B2 (en) 2010-02-23
CN101128461A (zh) 2008-02-20
HRP20100677T1 (hr) 2011-01-31
AU2006216710B2 (en) 2011-08-11
BRPI0609047A2 (pt) 2010-11-16
AR056186A1 (es) 2007-09-26
CN101128461B (zh) 2010-12-22

Similar Documents

Publication Publication Date Title
DK1904494T3 (da) Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
DK3106463T6 (da) Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
DK2350075T3 (da) Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
DK2057154T3 (da) PYRIDO-(2,3-B)pyrazinderivater, der er anvendelige som herbicidale forbindelser
DK2201012T3 (da) Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
IL204720A0 (en) Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors
DK1893612T3 (da) Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
DK2118101T3 (da) IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
EP1732566A4 (en) 6-azaindole COMPOUND
EP1939194A4 (en) AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
ZA200802497B (en) Imidazo [1,2-A] pyridine having anti-cell-proliferation actvity
DK2270008T3 (da) 8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-oner som PI-3-kinaseinhibitorer
HK1133654A1 (en) Pyridin-4-yl derivatives as immunomodulating agents
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1753764T3 (da) Pyrrolopyridin-derivater
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1948661T3 (da) Pyrazolo[4,3-D]pyrimidin-5-YL)-derivat anvendt som PDE5-inhibitorer
DK1814880T3 (da) Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
DK1680425T3 (da) 6-[(substitueret)phenyl]triazolopyrimidiner som anticancermidler